Reviving the FDA: NEJM perspective

Oct 06, 2010

In a Perspective piece published online today in the New England Journal of Medicine, Georgetown University School of Medicine family medicine physician Susan Okie gives a comprehensive overview of change, and planned change, within the Food and Drug Administration (FDA). The review comes as the FDA's commissioner, Margaret Hamburg, completes her first year as the agency's leader.

Okie writes that the FDA's priorities over the past year have included "finding ways to make the FDA more nimble and proactive, restoring its and refocusing staff on its public health mission, persuading Congress to boost funding for its expanding portfolio of responsibilities, [and] sharpening its ability to deal with new science and globalization…"

To that end, Hamburg reportedly has spent hundreds of hours meeting with interest groups and meeting with key members of Congress to build alliances.

As Okie outlines, Hamburg and the deputy commissioner, Joshua Sharfstein, have already undertaken several changes at the agency. The two leaders have met with FDA employees to understand hurdles they encounter because of legal and regulatory requirements. Such discussions have prompted new measures to accelerate responses to urgent health threats. In nonemergency situations, changes that have been described as "nuanced" actions often achieve desired results, Sharfstein says.

Hamburg, Sharfstein and internal task forces have been "reexamining the processes for making decisions" about the safety and effectiveness of drugs and medical devices. Okie says the agency is awaiting reports next year by Institute of Medicine panels that are likely to recommend reforms. The leadership anticipates decisions that could lead to lasting changes at the agency.

Finally, Hamburg's longer-term priorities include regulatory science and globalization. The Commissioner tells Okie that in addition to advocating for increased funding, the agency hopes to collaborate with scientists in academia and industry, as well as other federal health agencies, on research and training in areas such as biomarker, bioimaging, clinical-trial analytics and pharmacoepidemiology.

As for , Okie reports that the agency is introducing a risk-based strategy for targeting priority inspections in order to "grapple with the expanding task of ensuring the safety of products… made overseas."

Hamburg says despite the criticism of her agency and the growing pains within "...overseas, the FDA is still considered the gold standard for a regulatory agency," while here at home she says, "I have encountered a sense of real eagerness... to support the FDA in its mission."

Explore further: Italian army to grow medical marijuana

add to favorites email to friend print save as pdf

Related Stories

FDA stresses need to modernize its science

Oct 06, 2010

(AP) -- The Food and Drug Administration must update its scientific tools for reviewing prescription drugs, medical devices and tracking food safety, according to a list of priorities laid out Wednesday by agency leadership.

FDA Web site explains agency operations to public

Jan 12, 2010

(AP) -- The Food and Drug Administration is launching a new Web site explaining its operations to consumers as part of a broader effort to rebrand itself as a more accessible agency.

New FDA chiefs stress science, better food safety

May 26, 2009

(AP) -- The huge salmonella outbreak from peanut butter represented a failure of the Food and Drug Administration, that agency's new chiefs declared Tuesday - one they hope to fix.

FDA drug approvals mostly flat in 2009

Jan 05, 2010

(AP) -- Drug approvals from the Food and Drug Administration were flat last year compared with 2008 and warnings fell, even as the agency's new leadership struck a tougher stance on safety.

Drug industry advocates join chorus to split FDA

Mar 22, 2009

(AP) -- As momentum builds to rework the nation's food-safety system after a salmonella outbreak linked to peanuts, the drug industry is hoping for a happy side effect: faster approvals for new medicines.

Recommended for you

Non-stop PET/CT scan provides accurate images

23 hours ago

Siemens is improving PET/CT imaging and data quality while reducing radiation exposure. The Biograph mCT Flow PET/CT scanner is a new positron emission tomography/computed tomography (PET/CT) system that, ...

Experts: Chopin's heart shows signs of TB

Sep 17, 2014

The preserved heart of composer Frederic Chopin contains signs of tuberculosis and possibly some other lung disease, medical experts said Wednesday.

The argument in favor of doping

Sep 17, 2014

Ahead of Friday's court ruling on whether ASADA's investigation into the Essendon Football Club was lawful, world leader in practical and medical ethics Professor Julian Savulescu, looks at whether there is a role for performance-enhancing ...

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

Justsayin
not rated yet Oct 16, 2010
"boost funding" appears multiple times in this article but when you give more money to an incompetent and corrupt agency you get more incompetence and corruption. The FDA stifles new cancer drug development, delay approvals driving up the costs to astronomical levels and with all of these delays what is the real cost in lives. The story of 19 year old Abigail Burroughs says it all here...http://www.abigai...tory.php
Justsayin
not rated yet Oct 16, 2010
this is the link I meant to post http://www.lef.or...s_01.htm